Valeant Pharmaceuticals Intl Coverage Initiated at Jefferies Group (VRX)
Investment analysts at Jefferies Group started coverage on shares of Valeant Pharmaceuticals Intl (NYSE:VRX) in a note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “buy” rating and a $153.00 price target on the stock. Jefferies Group’s price objective would indicate a potential upside of 12.99% from the company’s current price.
Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 135.41 on Tuesday. Valeant Pharmaceuticals Intl has a 1-year low of $71.99 and a 1-year high of $153.10. The stock has a 50-day moving average of $132. and a 200-day moving average of $123.4. The company’s market cap is $45.345 billion.
Valeant Pharmaceuticals Intl (NYSE:VRX) last announced its earnings results on Thursday, February 27th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.09. The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $986.30 million. During the same quarter in the previous year, the company posted $1.22 earnings per share. The company’s revenue for the quarter was up 109.2% on a year-over-year basis. On average, analysts predict that Valeant Pharmaceuticals Intl will post $8.69 earnings per share for the current fiscal year.
A number of other analysts have also recently weighed in on VRX. Analysts at Cantor Fitzgerald initiated coverage on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, March 27th. They set a “buy” rating and a $200.00 price target on the stock. Separately, analysts at UBS AG raised their price target on shares of Valeant Pharmaceuticals Intl from $141.00 to $170.00 in a research note on Friday, February 28th. They now have a “buy” rating on the stock. Finally, analysts at RBC Capital raised their price target on shares of Valeant Pharmaceuticals Intl from $151.00 to $158.00 in a research note on Friday, February 28th. They now have an “outperform” rating on the stock. One investment analyst has rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average price target of $141.74.
Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.